The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 361:1118-1119 September 10, 2009 Number 11
NextNext

Autologous Stem-Cell Transplantation for Multiple Myeloma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Harousseau, J.-L.
-PubMed Citation
To the Editor: In the last sentence of their review article, Harousseau and Moreau (June 18 issue)1 state that the patient they describe had no adverse prognostic factors. However, the patient actually had three such adverse factors: a deletion of chromosome 13, a β2-microglobulin level of 2.8 mg per liter, and a hemoglobin level of 9.8 g per deciliter.2 In a study of 110 patients undergoing autologous stem-cell transplantation for myeloma, the two most powerful adverse prognostic factors were a monosomy or deletion of chromosome 13 and a serum β2-microglobulin level of more than 2.5 mg per liter. . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.